Влияние подкожного семаглутида в сравнении с плацебо в качестве дополнения к интенсивной поведенческой терапии на массу тела у взрослых с избыточной массой тела или ожирением
Рандомизированное клиническое исследование STEP 3
Перевод Г.Е. Заика (09.04.2024)
References
1. Jensen MD, Ryan DH, Apovian CM, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society . 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation. 2014;129(25)(suppl 2):S102-S138. doi: 10.1161/01.cir.0000437739.71477.ee [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27(5):537-549. doi: 10.1038/sj.ijo.0802258 [PubMed] [CrossRef] [Google Scholar]
3. Wadden TA, Foster GD, Sarwer DB, et al.. Dieting and the development of eating disorders in obese women: results of a randomized controlled trial. Am J Clin Nutr. 2004;80(3):560-568. doi: 10.1093/ajcn/80.3.560 [PubMed] [CrossRef] [Google Scholar]
4. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group . Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. doi: 10.2337/dc10-2415 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Garvey WT, Mechanick JI, Brett EM, et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines . American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203. doi: 10.4158/EP161365.GL [PubMed] [CrossRef] [Google Scholar]
6. Ryan DH, Yockey SR. Weight loss and improvements in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-194. doi: 10.1007/s13679-017-0262-y [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Gregg EW, Chen H, Wagenknecht LE, et al.; Look AHEAD Research Group . Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489-2496. doi: 10.1001/jama.2012.67929 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Kuna ST, Reboussin DM, Strotmeyer ES, et al.; Sleep AHEAD Research Subgroup of the Look AHEAD Research Group . Effects of weight loss on obstructive sleep apnea severity: ten-year results of the Sleep AHEAD study. Am J Respir Crit Care Med. 2021;203(2):221-229. doi: 10.1164/rccm.201912-2511OC [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Wadden TA, Walsh OA, Berkowitz RI, et al.. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring). 2019;27(1):75-86. doi: 10.1002/oby.22359 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Wadden TA, Tronieri JS, Sugimoto D, et al.. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28(3):529-536. doi: 10.1002/oby.22726 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use [prescribing information]. Accessed September 25, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
12. Ahmann AJ, Capehorn M, Charpentier G, et al.. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258-266. doi: 10.2337/dc17-0417 [PubMed] [CrossRef] [Google Scholar]
13. Ahrén B, Masmiquel L, Kumar H, et al.. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X [PubMed] [CrossRef] [Google Scholar]
14. O’Neil PM, Birkenfeld AL, McGowan B, et al.. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2 [PubMed] [CrossRef] [Google Scholar]
15. Kushner RF, Calanna S, Davies M, et al.. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. doi: 10.1002/oby.22794 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Food and Drug Administration. Guidance for industry: developing products for weight management. Accessed January 20, 2021. https://www.fda.gov/media/71252/download
17. Food and Drug Administration. E9(R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials. Accessed October 22, 2020. https://www.fda.gov/media/108698/download
18. Wharton S, Astrup A, Endahl L, et al.. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. Int J Obes (Lond). Published online January 18, 2021. doi: 10.1038/s41366-020-00733-x [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 2016;26(1):30-36. doi: 10.1080/10543406.2015.1094814 [PubMed] [CrossRef] [Google Scholar]
20. Rubin DB. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons; 1987. doi: 10.1002/9780470316696 [CrossRef] [Google Scholar]
21. Webb VL, Wadden TA. Intensive lifestyle intervention for obesity: principles, practices, and results. Gastroenterology. 2017;152(7):1752-1764. doi: 10.1053/j.gastro.2017.01.045 [PubMed] [CrossRef] [Google Scholar]
22. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183-197. doi: 10.1016/j.mcna.2017.08.012 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Leibel RL, Seeley RJ, Darsow T, Berg EG, Smith SR, Ratner R. Biologic responses to weight loss and weight regain: report from an American Diabetes Association research symposium. Diabetes. 2015;64(7):2299-2309. doi: 10.2337/db15-0004 [PubMed] [CrossRef] [Google Scholar]
24. Heckman BW, Mathew AR, Carpenter MJ. Treatment burden and treatment fatigue as barriers to health. Curr Opin Psychol. 2015;5:31-36. doi: 10.1016/j.copsyc.2015.03.004 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Sumithran P, Prendergast LA, Delbridge E, et al.. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. doi: 10.1056/NEJMoa1105816 [PubMed] [CrossRef] [Google Scholar]
26. Gabery S, Salinas CG, Paulsen SJ, et al.. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. doi: 10.1172/jci.insight.133429 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. doi: 10.1111/dom.14280 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336-347. doi: 10.1111/dom.12824 [PubMed] [CrossRef] [Google Scholar]
29. Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211-R234. doi: 10.1530/EJE-19-0566 [PubMed] [CrossRef] [Google Scholar]
30. Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med. 1995;98(2):115-117. doi: 10.1016/S0002-9343(99)80394-5 [PubMed] [CrossRef] [Google Scholar]
31. Wilding JPH, Batterham RL, Calanna S, et al.; the STEP 1 Study Group . Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. Published February 10, 2021. doi: 10.1056/NEJMoa2032183 [PubMed] [CrossRef] [Google Scholar]
© 2021 American Medical Association. All rights reserved.
eAppendix 1. Список исследователей в исследовании «Эффект лечения семаглутидом у людей с ожирением» (STEP) 3
United States of America: Carlos Arauz-Pacheco, Carlos Arauz-Pacheco MD, PA, Rockwall, Texas;
Stephen Aronoff, Research Institute of Dallas, Dallas, Texas; Timothy Bailey, AMCR Institute, Inc.,
Escondido, California; Liana Billings, NorthShore University HealthSystem, Skokie, Illinois; Bruce Bowling,
Regional Clinical Research, Inc., Endwell, New York; Kevin Cannon, PMG Research of Wilmington, LLC,
Wilmington, North Carolina; Christopher Chappel, The Chappel Group Research, Kissimmee, Florida;
Mark Christiansen, Diablo Clinical Research, Inc., Walnut Creek, California; Kenneth Cohen, New West
Physicians, Inc., Golden, Colorado; John Earl, PMG Research of Hickory, LLC, Hickory, North Carolina;
Valerie Espinosa, Texas Diabetes & Endocrinology, P.A., Austin, Texas; David Fitz-Patrick, East West
Medical Research Institute, Honolulu, Hawaii; George Freeman, Health Research of Hampton Roads, Inc.,
Newport News, Virginia; Juan Frias, National Research Institute, Los Angeles, California; W. Timothy
Garvey, University of Alabama at Birmingham, Birmingham, Alabama; Jeffrey Geohas, Evanston Premier
Healthcare Research, LLC, Evanston, Illinois; Gregg Gerety, Albany Medical College, Division of
Community Endocrinology, Albany, New York; John Gilbert, St. Joseph Heritage Healthcare, Fullerton,
California; Amina Haggag, Anaheim Clinical Trials, LLC, Anaheim, California; Priscilla Hollander, Baylor
Scott & White Endocrine Center, Dallas, Texas; Misal Khan, Misal Khan MD FRCS (ED) P.A., Panama
City, Florida; Eric Klein, Capital Clinical Research Center, LLC, Olympia, Washington; Karen Laufer,
Clinical Trial Research Associates, Inc., Plantation, Florida; Sriram Machineni, University of North
Carolina, Chapel Hill, North Carolina; Paul Norwood, Valley Research, Fresno, California; Philip O'Donnell,
Selma Medical Associates, Winchester, Virginia; Patrick O’Neil, Medical University of South Carolina,
Charleston, South Carolina; Robert Orr, Phoenix Medical Group, Peoria, Arizona; Walter Pharr, Medication
Management, LLC, Greensboro, North Carolina; John Reed III, Endocrine Research Solutions, Inc.,
Roswell, Georgia; Paul Rosenblit, Diabetes/Lipid Management & Research Center, Huntington Beach,
California; Julio Rosenstock, Dallas Diabetes Research Center, Dallas, Texas; Domenica Rubino,
Washington Center for Weight Management and Research, Inc., Arlington, Virginia; John Rubino, Triangle
Medical Research Associates, Raleigh, North Carolina; William Sargeant, Healthscan Clinical Trials, LLC,
Montgomery, Alabama; Stephanie Shaw, Texas Diabetes & Endocrinology, P.A., Round Rock, Texas;
Cynthia Strout, Coastal Carolina Research Center, Mt. Pleasant, South Carolina; Danny Sugimoto, Cedar-
Crosse Research Center, Chicago, Illinois; Thomas Wadden, Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, Pennsylvania; Paul Wakefield, PMG Research of Knoxville,
Knoxville, Tennessee; and Joseph Woolley, Chrysalis Clinical Research, St. George, Utah.